Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibAdam J. Schoenfeld, Matthew D. Hellmann, Shirish M. Gadgeel et al.|Annals of Oncology|2019Cited by 413
COVID-19 in patients with lung cancerJie Luo, Matthew D. Hellmann, Hira Rizvi et al.|Annals of Oncology|2020Cited by 269